Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

56.03
BATS BZX Real-Time Price
As of 12:56pm ET
 -0.33 / -0.59%
Today’s Change
46.01
Today|||52-Week Range
77.12
-4.12%
Year-to-Date
Infinity Pharma Focuses on Cancer Drug: Competition Looms
Mar 21 / Zacks.com - Paid Partner Content
Dow, Nasdaq Rise as FBI's Comey Confirms Probe of Russia's Election Interference
Mar 20 / TheStreet.com - Paid Partner Content
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
Mar 21 / Zacks.com - Paid Partner Content
CytomX Soars on Bristol-Myers Partnership
Mar 20 / TheStreet.com - Paid Partner Content
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar 21 / Zacks.com - Paid Partner Content
Stock Futures Slip After G20 Meeting Raises Fears of Protectionism
Mar 20 / TheStreet.com - Paid Partner Content
Dodge & Cox Buys Bristol-Myers Squibb Company, Zayo Group Holdings, Medtronic PLC, Se...
Mar 20 / GuruFocus News - Paid Partner Content
European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
Mar 20 / TheStreet.com - Paid Partner Content
Stocks Lower as Crude Slump Weighs on Energy Sector
Mar 20 / TheStreet.com - Paid Partner Content
European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar 20 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close56.36
Today’s open55.95
Day’s range55.94 - 56.51
Volume357,995
Average volume (3 months)11,968,290
Market cap$94.3B
Dividend yield2.78%
Data as of 12:56pm ET, 03/23/2017

Growth & Valuation

Earnings growth (last year)+184.95%
Earnings growth (this year)-0.84%
Earnings growth (next 5 years)+17.65%
Revenue growth (last year)+17.31%
P/E ratio21.1
Price/Sales5.05
Price/Book5.80

Competitors

 Today’s
change
Today’s
% change
LLYEli Lilly and Co+0.58+0.69%
CELGCelgene+0.50+0.41%
GSKGlaxoSmithKline+0.19+0.45%
ABBVAbbVie+0.32+0.49%
Data as of 12:56pm ET, 03/23/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$0.73
Annual revenue (last year)$19.4B
Annual profit (last year)$4.5B
Net profit margin22.94%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts


Search for Jobs